Rituximab: Current status as therapy for malignant and Benign hematologic disorders

Nihal E. Abdulla, Mary J. Ninan, Avi B. Markowitz

    Research output: Contribution to journalReview articlepeer-review

    14 Scopus citations


    Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.

    Original languageEnglish (US)
    Pages (from-to)71-82
    Number of pages12
    Issue number2
    StatePublished - 2012


    • Chronic-lymphocytic-leukaemia
    • Diffuse-large-B-cell-lymphoma
    • Follicular-lymphoma
    • Haematological-disorders
    • Lymphoma
    • Rituximab

    ASJC Scopus subject areas

    • Biotechnology
    • Pharmacology
    • Pharmacology (medical)


    Dive into the research topics of 'Rituximab: Current status as therapy for malignant and Benign hematologic disorders'. Together they form a unique fingerprint.

    Cite this